Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Etirinotecan Pegol (NKTR-102) in NSCLC
Metastatic Non Small Cell Lung Cancer · Recurrent Non Small Cell Lung Cancer
Primary: Overall Objective Response Rate — 2; 17; 18 Participants
Phase 2 N=91 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy
Malignant Glioma
Primary: Proportion of Grade IV MGMT Un-methylated Patients That Experience Confirmed-progression-free Survival at 6 Months (CPFS6) — 0.795 proportion of participants
Phase 2 N=63 Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6 — -3.1; -63.6 percent change — p=<0.001
Phase 2 N=360 Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Insomnia Disorder
Primary: Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 — -28.4; -32.3; -37.7; -47.1 minutes — p=<0.001
Phase 2 N=87 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection
Smallpox
Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants
Phase 2 N=48 Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B
Chronic Hepatitis B
Primary: Percentage of Participants With ≥ 1 log10 IU/mL Decline in Serum Quantitative Hepatitis B Surface Antigen (qHBsAg) From Baseline at Week 24 — 0; 0; 0; 10.0 percentage of…
Phase 2 N=58 Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery
Female Reproductive Cancer
Primary: Time-to-QOL Improvement Defined as Any Increase in the QOL Score Measured Using the Total Score of the 14-item Postoperative Quality of Life (PQL) Tool — 4.86; 3.29 Months
Phase 2 N=27 Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Kidney Cancer
Primary: Overall Response Rate (ORR) — 70.4 percentage of participants
Phase 2 N=20 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Ovarian Endometrioid Adenocarcinoma · Ovarian Seromucinous Carcinoma · Ovarian Serous Cystadenocarcinoma
Primary: Percentage of Patients Alive and Progression Free Survival at 12 Weeks — 47 percentage of patients
Phase 2 N=50 Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
Her2-Positive Breast Cancer
Primary: Proportion of Participants With a Pathologic Complete Response Rate — .26; .80 proportion of participants
Phase 2 N=400 Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
Gynecologic Cancer · Venous Thromboembolism
Primary: Number of Participants With Incidence of Major Bleeding — 1; 1 Participants
Phase 2 N=711 Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind…
Phase 2 N=17 Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Leukemia · Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose (MTD) of Selinexor With Sorafenib — 60; 60 Milligrams
Phase 2 N=62 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Participants With Adverse Events — 6; 0; 3; 2 Participants